The burden of progressive fibrotic interstitial lung disease across the UK.
Author
Simpson, ThomasBarratt, Shaney L
Beirne, Paul
Chaudhuri, Nazia
Crawshaw, Anjali
Crowley, Louise E
Fletcher, Sophie
Gibbons, Michael A
Hallchurch, Philippa
Horgan, Laura
Jakaityte, Ieva
Lewis, Thomas
McLellan, Tom
Myall, Katherine J
Miller, Ryan
Smith, David J F
Stanel, Stefan
Thillai, Muhunthan
Thompson, Fiona
Wallis, Timothy
Wu, Zhe
Molyneaux, Philip L
West, Alex G
Publication date
2021-07-08Subject
Respiratory medicine
Metadata
Show full item recordAbstract
Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClNCitation
Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, Fletcher S, Gibbons MA, Hallchurch P, Horgan L, Jakaityte I, Lewis T, McLellan T, Myall KJ, Miller R, Smith DJF, Stanel S, Thillai M, Thompson F, Wallis T, Wu Z, Molyneaux PL, West AG. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021Type
ArticleAdditional Links
https://erj.ersjournals.com/PMID
33678609Journal
The European Respiratory JournalPublisher
European Respiratory Societyae974a485f413a2113503eed53cd6c53
10.1183/13993003.00221-2021